Digitization Is Defining a New Era for the Pharmacovigilance Sector
Being able to monitor adverse drug reactions is vital to the ongoing development of the life sciences sector and something that is a focus for patients, clinicians and regulatory agencies. Data is vital to this process - the collection of real-world data can inform everything, from black box warnings to drugs being withdrawn from the market as a result of pharmacovigilance processes. Today, there is a wealth of technology to make this system even more effective and this digitization is...
View full press release